公开(公告)号：US20240217979A1

公开(公告)日：2024-07-04

申请号：US18287844

申请日：2022-04-21

申请人： Emory University

发明人： Dennis C. Liotta ,  Stephen F. Traynelis ,  David S. Menaldino ,  Peipei Ma

IPC分类号： C07D487/04 ,  A61K31/415 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5025 ,  A61K31/519 ,  C07D231/06 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D487/04 ,  A61K31/415 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5025 ,  A61K31/519 ,  C07D231/06 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

摘要： Compounds that selectively inhibit the GluN2 subunits of NMDA receptors are disclosed. In general, the compounds have superior activity against GluN2C/D subunit(s) over GluN2A/B subunit(s). Optionally, the compounds have a structure of Formulas (I), (II), (III), or other formulas disclosed herein, enantiomers or diastereomers thereof, or pharmaceutically acceptable salts thereof. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a neurological condition or disorder using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary neurological conditions or disorders include Parkinson's disease, dystonia and related motor disorders, depression, neuropsychiatric indications, stoke, hypoxia, traumatic brain injury, acute injuries involving the white matter, Alzheimer's disease, compulsivity and related disorders, and epilepsy.